-
The frequency of chemotherapy-induced amenorrhea was found to be greater than 90% in premenopausal breast cancer patients treated with standard adjuvant chemotherapy.
-
-
Polypharmacy is a huge problem in U.S. health care and is compounded by the increasing use of supplements and herbal medications.
-
Carboplatin-pemetrexed doublet chemotherapy is effective primary treatment for patients with nonsquamous non-small cell lung cancer, but the applicability of standard dosing to older or more frail patients was uncertain.
-
Arthralgias and associated symptoms are common among postmenopausal breast cancer patients treated with aromatase inhibitors.
-
Selumetinib, a selective MEK1/2 inhibitor, achieved objective responses in 15% of patients with recurrent low-grade serous ovarian cancer. The data are relevant as this uncommon tumor type is associated with general chemoresistance, frequent aberration in the MAPK pathway, and prolonged overall survival compared with its more common high-grade variant. Phase 3 trials are planned.
-
-
Carboplatin-pemetrexed doublet chemotherapy is effective primary treatment for patients with nonsquamous non-small cell lung cancer, but the applicability of standard dosing to older or more frail patients was uncertain.
-
In a large population of Caucasian women participating in the Womens Health Initiative Observational Study, those who used aspirin had a significantly lower risk of melanoma and increased duration of use was associated with incrementally greater protection.
-
Ten years of adjuvant tamoxifen is significantly better than the standard 5 years of treatment. Continuing adjuvant tamoxifen for 10 years substantially reduces rates of both recurrence and breast cancer-specific mortality in women with estrogen receptor-positive breast cancer.